Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › leuprorelin

leuprorelin

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of leuprorelin

12 trials tracked of leuprorelin: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 97 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 1 Other / NA 6
  1. Phase 3 A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Completed · 97 cited
  2. Phase 4 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants Completed · 5 cited
  3. Phase 3 Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature Completed
  4. Phase 3 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer Completed
  5. Phase 3 PGL4001 Versus GnRH-agonist in Uterine Myomas Completed
  6. Phase 2 A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer Completed
Show 6 more trials
  1. N/A Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)" Completed
  2. N/A Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland Completed
  3. N/A Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer" Completed
  4. N/A Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" Completed
  5. N/A Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients" Completed
  6. N/A Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)" Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Toripalimab shows biochemical and radiographic response in a patient with MSI-H mCRPC
Oncology Sys. Review
Toripalimab shows biochemical and radiographic response in a patient with MSI-H mCRPC Toripalimab shows promise for a patient with advanced prostate cancer
This case report describes a 79-year-old male with MSI-H/TMB-H metastatic castration-resistant prostate cancer treated with toripalimab and …
A 79-year-old man with advanced prostate cancer saw significant tumor shrinkage and improved lab results after receiving toripalimab treatme…
Frontiers Oct 10, 2026
Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence
Drug Pipeline RCT
Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence Enzalutamide shows better outcomes than leuprolide for high risk prostate cancer recurrence
This Phase 3 randomized controlled trial evaluated enzalutamide monotherapy versus leuprolide alone in patients with high-risk biochemical r…
Men with high-risk prostate cancer recurrence lived longer and spread less cancer when taking enzalutamide alone instead of leuprolide alone…
Apr 19, 2026
Network meta-analysis finds GnRHa trigger reduces OHSS risk versus hCG in predicted high responders undergoing IVF
Diabetes & Endocrinology Meta-analysis
Network meta-analysis finds GnRHa trigger reduces OHSS risk versus hCG in predicted high responders undergoing IVF Study compares four IVF trigger methods for women at high risk of over-response
A network meta-analysis of 7 RCTs involving 632 predicted high responders undergoing IVF with GnRH antagonist protocols compared four final …
For women at high risk of painful IVF complications, a specific hormone trigger shot significantly lowers that risk without reducing egg cou…
Frontiers Apr 8, 2026